Advice
in the absence of a submission from the holder of the marketing authorisation:
zonisamide (Zonegran®) is not recommended for use within NHS Scotland.
Indication under review: monotherapy for the treatment of partial seizures (with or without secondary generalization) in adults with newly diagnosed epilepsy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice39KB (PDF)
Medicine details
- Medicine name:
- zonisamide (Zonegran)
- SMC ID:
- 817/12
- Indication:
- monotherapy for the treatment of partial seizures (with or without secondary generalization) in adults with newly diagnosed epilepsy.
- Pharmaceutical company
- Eisai Ltd
- BNF chapter
- Central nervous system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 October 2012